Meriem Yazidi

Dr. Meriem Yazidi


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2024 in Endocrine
Verified
Journal Article
Closed access
PDF file
FCFaten Cherchir
Faten Cherchir
IOIbtissem Oueslati
Ibtissem Oueslati
MYMeriem Yazidi
Meriem Yazidi
FCFatma Chaker
Fatma Chaker
HMHabiba Mizouni
Habiba Mizouni
MCMelika Chihaoui
Melika Chihaoui

23 March 2022 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
MYMeriem Yazidi
Meriem Yazidi
SMSana Mahjoubi
Sana Mahjoubi
IOIbtissem Oueslati
Ibtissem Oueslati
FCFatma Chaker
Fatma Chaker
MCMelika Chihaoui
Melika Chihaoui
Objective: There is little data about the remission phase in adolescents and young adults with newly diagnosed type 1 diabetes mellitus (T1D). The aims of this study were to determine the prevalence of remission and its predicting factors among adolescents and young adults with newly diagnosed T1D and to assess the association between remission and long-term glycemic control in this population. Subjects and methods: This is a longitudinal and retrospective study including 128 type 1 diabetic patients aged between [...] ABSTRACT Objective: There is little data about the remission phase in adolescents and young adults with newly diagnosed type 1 diabetes mellitus (T1D). The aims of this study were to determine the prevalence of remission and its predicting factors among adolescents and young adults with newly diagnosed T1D and to assess the association between remission and long-term glycemic control in this population. Subjects and methods: This is a longitudinal and retrospective study including 128 type 1 diabetic patients aged between

19 June 2023 in Chronic Illness
Verified
Journal Article
Closed access
MYMeriem Yazidi
Meriem Yazidi
EKElyes Kamoun
Elyes Kamoun
STSameh Hadj Taieb
Sameh Hadj Taieb
OROns Rejeb
Ons Rejeb
SMSonia Mahjoub
Sonia Mahjoub
MCMelika Chihaoui
Melika Chihaoui
Objectives: To determine the prevalence of vitamin B12 deficiency in a Tunisian population with type 2 diabetes (T2D) on metformin treatment for more than three years and to identify its risk factors. Methods: This is a cross-sectional study conducted on 257 patients with T2D treated with metformin for at least three years. Patients were divided into two groups according to their vitamin B12 status. Low vitamin B12 was defined as ≤ 203 pg/mL. Results: The mean age of the patients was 59.8 ± 7.9 years. The mean duration of metformin use was 10.2 ± 5.2 years. The mean vitamin B12 level was 294.9 ± 156.4 pg/mL. The prevalence of vitamin B12 deficiency was 28.4%. Male gender, HbA1c < 7% and hyperhomocysteinemia were significantly associated with vitamin B12 deficiency (respectively p = 0.02, p < 0.001, p < 0.001). Homocysteine level was negatively correlated with vitamin B12 level ( r = −0.2, p = 0.001). Dose and duration of metformin treatment, peripheral neuropathy and anemia were not associated with vitamin B12 deficiency. On multivariate analysis, HbA1c < 7% and hyperhomocysteinemia were independently associated with vitamin B12 deficiency (respectively OR = 3.2, 95%CI = [1.6–6.3] and OR = 2.3, 95%CI = [1.2–4.2]). Discussion: The prevalence of vitamin B12 deficiency in patients with T2D on metformin treatment was high. Hyperhomocysteinemia is associated with vitamin B12 deficiency suggesting that the deficit occurs at the tissue level.

20 July 2024 in Korean Journal of Family Medicine
Verified
Journal Article
Open access
PDF file
MYMeriem Yazidi
Meriem Yazidi
EKElyes Kammoun
Elyes Kammoun
IOIbtissem Oueslati
Ibtissem Oueslati
MCMelika Chihaoui
Melika Chihaoui
Metformin is the most widely used antihyperglycemic drug in patients with type 2 diabetes (T2D). Over the past 2 decades, several studies have highlighted a substantial increase in the risk of vitamin B12 deficiency in patients with T2D on metformin therapy. This can lead to several complications and induce or exacerbate peripheral neuropathy. Despite these data, there are no definite guidelines for screening, diagnosing, and treating vitamin B12 deficiency in patients with T2D on metformin therapy. Therefore, in this narrative review, we aimed to suggest a practical diagnostic and therapeutic strategy to address vitamin B12 deficiency in patients with T2D receiving metformin treatment. Clinical evidence supporting an increased risk of vitamin B12 deficiency in patients with T2D on metformin therapy and its risk factors and potential complications are also discussed.

1 July 2022 in Endocrine Regulations
Verified
Journal Article
Open access
PDF file
MYMeriem Yazidi
Meriem Yazidi
CDCyrine Danguir
Cyrine Danguir
DMDhouha Maamer
Dhouha Maamer
IOIbtissem Oueslati
Ibtissem Oueslati
KKKarima Khiari
Karima Khiari
MCMelika Chihaoui
Melika Chihaoui
Objective. The study was aimed to assess the effect of hydrocortisone (HC) replacement therapy on bone mineral density (BMD) and bone turnover markers in patients with primary adrenal insufficiency (PAI). Methods. A cross-sectional study was conducted in 37 PAI patients treated with HC. BMD and selected bone turnover markers (β-crosslaps and osteocalcin) were measured. A stepwise binary logistic regression model was applied to determine the independent variables associated with low BMD. Results. Osteoporosis was noted in 14.3% and osteopenia in 34.3% of cases. These patients were older (p=0.01) and received higher daily HC dose compared to patients with normal BMD (p=0.01). BMD values in the lumbar spine and the femoral neck were negatively correlated with daily HC dose (r=–0.36, p=0.03 and r=–0.34, p=0.05, respectively). Plasma osteocalcin was negatively correlated with disease duration (r=–0.38, p=0.02) and cumulative HC dose (r=–0.43, p<0.01). In multivariate analysis, a daily HC dose ≥12 mg/m2/day was independently associated with a higher risk of osteopenia/osteoporosis [OR (95% CI), 9.0 (1.1–74.6); p=0.04]. Conclusions. Impaired bone mineralization in patients with PAI is correlated with HC dose. A daily HC dose ≥12 mg/m 2 /day was associated with an increased risk of osteopenia and osteoporosis in these patients.

16 June 2023 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
HCHiba‐Allah Chatti
Hiba‐Allah Chatti
IOIbtissem Oueslati
Ibtissem Oueslati
AAAymen Azaiez
Aymen Azaiez
JMJihen Marrakchi
Jihen Marrakchi
SBSeif Boukriba
Seif Boukriba
MCMelika Chihaoui
Melika Chihaoui
Introduction: Several ultrasound scoring systems have been developed to stratify the risk of malignancy of thyroid nodules, including ACR (American College of Radiology) and EU (European) TI‐RADS. This study aimed to assess the diagnostic performance of these two classifications using histology as a reference standard.Methods: It was a single‐centre, retrospective study including 156 patients who underwent thyroidectomy. Ultrasound data of 198 nodules (99 malignant nodules and 99 benign nodules) were analysed. Both classifications were applied for all nodules.Results: Ultrasound criteria associated with malignancy were solid composition (OR=7.81; p < 10−3), hypoechoic character (OR=16.42; p < 10−3), irregular contours (OR=7.47; p < 10−3), taller‐than‐wide shape (OR=3.58; p = 0.02), microcalcifications (OR=3.02; p = .006) and the presence of cervical adenopathy (OR=3.89; p = .006). The prevalence of malignancy was 15.5%, 69% and 76.9% for EU TI‐RADS categories 3, 4 and 5, respectively. It was 33.3%, 57% and 91.1% for ACR TI‐RADS categories 3, 4 and 5, respectively. For category 5, EU TI‐RADS and ACR TI‐RADS had sensitivities of 60% and 41%, specificities of 82% and 96%, respectively. For categories 4 and 5 combined, the diagnostic performance of these two classification systems became comparable with a sensitivity of 89% and 86% for EU‐TIRADS and ACR‐TIRADS, respectively. The area under the ROC curve was 0.81 for the EU TI‐RADS classification and 0.82 for the ACR TI‐RADS classification.Conclusions: EU TI‐RADS and ACR TI‐RADS scoring systems seem to be comparable in predicting malignancy in thyroid nodules.